Isoliquiritigenin mitigates inflammatory responses by upregulating Sirt-1 activity and modulating the NF-κB and NLRP3 pathways, leading to reduced collagen accumulation in diabetic kidney disease and safeguarding renal architecture and functionality (170). Here, SIRT1 is linked to diabetic kidney disease.